Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 297.34% | -146.23% | 68.55% | -89.77% | 27.79% |
| Total Depreciation and Amortization | 0.00% | -3.70% | 3.85% | -3.70% | 3.85% |
| Total Amortization of Deferred Charges | -24.32% | 3.29% | 17.31% | 306.40% | -61.52% |
| Total Other Non-Cash Items | -21.84% | -23.06% | 33.39% | -32.12% | 21.62% |
| Change in Net Operating Assets | -201.71% | 179.69% | -318.76% | 156.45% | -71.56% |
| Cash from Operations | 1,155.60% | 86.36% | -38.86% | 35.26% | 1.06% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 694.88% | 274.46% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -105.16% | 1,610.54% |
| Cash from Financing | 182.63% | 274.46% | 138.00% | -121.43% | 484.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,080.79% | 122.35% | 5.16% | -68,572.73% | 100.10% |